Motor neuron disease: systematic reviews of treatment for ALS and SMA
Open Access
- 15 December 2009
- journal article
- review article
- Published by Oxford University Press (OUP) in British Medical Bulletin
- Vol. 93 (1), 145-159
- https://doi.org/10.1093/bmb/ldp049
Abstract
IntroductionThere is no curative treatment for the common motor neuron diseases, amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy. Nevertheless, there is an increasing volume of published studies. This review assesses the current evidence for treatment of these conditions.Sources of dataPrimarily, the systematic reviews of the Cochrane Collaboration, with additional reference to other systematic reviews and online sites.Areas of agreementRiluzole remains the only medication with demonstrated efficacy and regulatory approval for the treatment of ALS.Areas of controversy, growing points and areas timely for developing researchThe design of clinical trials and the publication of unsatisfactory studies, in both human and animal models, continue to cause confusion in advising on patient management. Improvements in trial design, critical assessment of studies for publication and avoidance of bias towards publication of positive results are needed. A better understanding of pathogenesis should lead to more potent interventions.Keywords
This publication has 34 references indexed in Scilit:
- Current hypotheses for the underlying biology of amyotrophic lateral sclerosisAnnals of Neurology, 2009
- High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind studyJournal of Neural Transmission, 2004
- A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosisZeitschrift für Neurologie, 2002
- A double-blind, placebo-controlled randomized clinical trial of α-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosisAmyotrophic Lateral Sclerosis, 2001
- A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosisNeurology, 1998
- Dose-ranging study of riluzole in amyotrophic lateral sclerosisThe Lancet, 1996
- A double‐blind placebo‐controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosisNeurology, 1996
- A placebo‐controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosisAnnals of Neurology, 1996
- Randomized, Double-Blind, Controlled Trial of Acetylcysteine in Amyotrophic Lateral SclerosisArchives of Neurology, 1995
- A Controlled Trial of Riluzole in Amyotrophic Lateral SclerosisNew England Journal of Medicine, 1994